Catalyst Bioscieences

Crescent Biopharma, Inc., a biotech firm innovating cancer therapies, develops CR‑001, a bispecific anti‑PD‑1/anti‑VEGF antibody for solid tumors, alongside CR‑002 and CR‑003, with partnerships to advance oncology therapeutics in the U.S.

Headquarters: United States (USA)

Catalyst Bioscieences Logo
Company Profile
  • Employees: 41
  • HQ: Waltham
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CBIO Catalyst Bioscieences
Cap: 0.3B
EQUITY NCM USD US14888D2080 Active
📈
Home Login